Australian and New Zealand Urogenital and Prostate Cancer Trials Group

Recent papers from Australian and New Zealand Urogenital and Prostate Cancer Trials Group

1. ENZARAD (ANZUP 1303): Phase 3 Trial of Enzalutamide With Androgen Deprivation Therapy and Radiation Therapy in High-Risk Localized or Locally Advanced Prostate CancerJournal of Clinical Oncology · 2026
2. Management and outcomes of renal colic in pregnancy: A 10-year Australian tertiary centre experienceJournal of Clinical Urology · 2026
3. Pembrolizumab and Denosumab in Clear-Cell Renal-Cell Carcinoma.2026
4. Development and Validation of a Computational Histology Artificial Intelligence–Powered Biomarker in Metastatic Hormone-Sensitive Prostate Cancer on Randomized Phase III TrialsJCO Precision Oncology · 2026
5. AI-Based Pathology classifier Predicts Sensitivity to Enzalutamide in Metastatic Hormone-Sensitive Prostate Cancer: A Biomarker Analysis of the ENZAMET TrialClinical Cancer Research · 2026
6. Assessment of the ability of Decipher Prostate Genomic Classifier (DGC) >0.85 to identify patients who benefit from adding docetaxel (DOC) to androgen deprivation therapy (ADT) plus enzalutamide (ENZ): Level 1B evidence from the ENZAMET study.Journal of Clinical Oncology · 2026
7. An AI-based pathology classifier to predict benefit from enzalutamide in metastatic hormone-sensitive prostate cancer (mHSPC) from ENZAMET (ANZUP 1304).Journal of Clinical Oncology · 2026
8. Germline genetic correlates in metastatic hormone-sensitive prostate cancer (mHSPC) treated with androgen deprivation therapy (ADT) plus non-steroidal anti-androgen (NSAA) or enzalutamide (ENZA): Correlative study of ENZAMET (ANZUP 1304).Journal of Clinical Oncology · 2026
9. Initial results from CLIMATE, a prospective cohort study assessing the clinical utility of miR-371a-3p (miR-371) as a marker of minimal residual disease (MRD) in clinical stage 1 testicular germ cell tumour (TGCT): ANZUP 1906.Journal of Clinical Oncology · 2026
10. Development and validation of computational histology artificial intelligence (CHAI)–powered prognostic and predictive biomarkers in metastatic hormone-sensitive prostate cancer (mHSPC) using ENZAMET and CHAARTED prospective randomized phase 3 trials (RCT).Journal of Clinical Oncology · 2026
11. Early favorable prostate-specific antigen response prediction in metastatic hormone sensitive prostate cancerNature Communications · 2025
12. The role of gemcitabine–docetaxel in the management of NMIBC: a scoping review of current status and future directionsExpert Review of Anticancer Therapy · 2025
13. The role of immune checkpoint inhibitors in the management of NMIBC: a scoping review of current status and future directionExpert Review of Anticancer Therapy · 2025
14. Target trial emulation of early docetaxel and enzalutamide for metastatic hormone‐sensitive prostate cancerBJU International · 2025
15. What matters to society when making decisions about reimbursing drugs for prostate cancer: a discrete choice experimentJNCI Journal of the National Cancer Institute · 2025
16. The Paradox of Data Sharing in Cancer Randomized Clinical Trials—A Call for Greater TransparencyJAMA Oncology · 2025
17. A selective inhibitor of oncogenic JNK signalling perturbs metastatic outgrowth of triple-negative breast cancer through metabolic blockade2025
18. Nuclear Medicine and Molecular Imaging in Urothelial Cancer: Current Status and Future DirectionsCancers · 2025
19. Symptoms and Side Effects of Bacille Calmette–Guerin Therapy for Non-Muscle Invasive Bladder Cancer as Reported by Patients: A Systematic ReviewCancers · 2025
20. Development of a new radical cystectomy surveillance protocol and nurse‐led cystectomy follow‐up clinic in AustraliaANZ Journal of Surgery · 2024